Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis
暂无分享,去创建一个
Jeffrey M. Trent | Darren Finlay | Kristiina Vuori | Kuan-Fu Ding | Emanuel F. Petricoin | Hongwei Yin | William P.D. Hendricks | Chris Sereduk | Jeffrey Kiefer | Aleksandar Sekulic | Patricia M. LoRusso | Nicholas J. Schork
[1] Trevor Hastie,et al. Computer Age Statistical Inference: Algorithms, Evidence, and Data Science , 2016 .
[2] Chad C. Brown,et al. An adaptive permutation approach for genome-wide association study: evaluation and recommendations for use , 2014, BioData Mining.
[3] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[4] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[5] Alana L. Welm,et al. Human Primary Tumorgraft Models : Comparisons with Traditional Oncology Pre-Clinical Models and The Clinical Relevance and Utility of Primary Tumorgrafts in Basic and Translational Oncology Research , 2013 .
[6] R. Shoemaker. The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.
[7] Michael P. Morrissey,et al. Pharmacogenomic agreement between two cancer cell line data sets , 2015, Nature.
[8] Erik Willems,et al. Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery , 2013, Circulation research.
[9] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[10] D. Bates,et al. Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.
[11] Darren Finlay,et al. Analysis of variability in high throughput screening data: applications to melanoma cell lines and drug responses , 2017, Oncotarget.
[12] Jeff Shrager,et al. Rapid learning for precision oncology , 2014, Nature Reviews Clinical Oncology.
[13] Yongcui Wang,et al. Inferences of drug responses in cancer cells from cancer genomic features and compound chemical and therapeutic properties , 2016, Scientific Reports.
[14] Benjamin Haibe-Kains,et al. Inconsistency in large pharmacogenomic studies , 2013, Nature.
[15] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[16] Levi A Garraway,et al. Precision oncology: an overview. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Yuri Nikolsky,et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue , 2012, Journal of Translational Medicine.
[18] N. Schork. Personalized medicine: Time for one-person trials , 2015, Nature.
[19] Chris Sander,et al. Spatial Normalization of Reverse Phase Protein Array Data , 2014, PloS one.
[20] Ramakant Sharma,et al. Phylogeny Estimation and Hypothesis Testing using Maximum Likelihood , 2003 .
[21] Jean-Pierre Gillet,et al. The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.
[22] P Hougaard,et al. Confidence bounds for nonlinear dose-response relationships. , 2015, Statistics in medicine.